Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taking on CMS

This article was originally published in RPM Report

Executive Summary

Amgen and J&J have billions of dollars at stake in the battle to convince CMS to change its coverage proposal for EPO in cancer patients. Win or lose, their efforts will be a valuable case study for any other manufacturer that fi nds itself facing an adverse reimbursement policy.

You may also be interested in...



Avoiding Another EPO: Amgen's Nplate Has FDA Restrictions, But May Escape Medicare Controls

The Centers for Medicare & Medicaid Services is considering national coverage restrictions for Amgen's newly approved Nplate (romiplostim). CMS is ostensibly concerned about a lack of long-term data. Based on Medicare's experience with previous Amgen products, CMS may also be worried about long-term costs. But Amgen says CMS there is no need for Amgen to get involved: FDA has the situation well in-hand with a REMS risk management program.

Leads & Contacts

Members of FDA Risk Communications Advisory Committee. Wyeth R&D senior execs meet with FDA drug review managers in September 2007. Oncologists, an ex-Congresswoman, and a former Bush Administration health policy advisor met with FDA senior managers (including Commissioner von Eschenbach) in October before FDA decidied to support the Centers for Medicare and Medicaid Services in its effort to restrict use of EPO for chemotherapy patients.

What's the Difference? Sepracor's Xopenex Hit Hard by Coverage Cut

Xopenex reimbursement is being slashed by Medicare. The message: CMS wants proof of differentiation before it will pay more for line extensions and new formulations. That means trouble ahead for a lot of other products.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel